TNFRSF18 and hepatocellular carcinoma: HCC patients in the high-PRDX1 group had elevated immune checkpoints, incorporating PDCD1LG2, CTLA4, TIGIT, LAIR1, CD86, CD47, TNFRSF9, TNFRSF18 and TNFRSF4 than the patients in the low-PRDX1 group (Figure 12B).